作者
Laura M Raffield, Hong Dang, Katherine A Pratte, Sean Jacobson, Lucas A Gillenwater, Elizabeth Ampleford, Igor Barjaktarevic, Patricia Basta, Clary B Clish, Alejandro P Comellas, Elaine Cornell, Jeffrey L Curtis, Claire Doerschuk, Peter Durda, Claire Emson, Christine M Freeman, Xiuqing Guo, Annette T Hastie, Gregory A Hawkins, Julio Herrera, W Craig Johnson, Wassim W Labaki, Yongmei Liu, Brett Masters, Michael Miller, Victor E Ortega, George Papanicolaou, Stephen Peters, Kent D Taylor, Stephen S Rich, Jerome I Rotter, Paul Auer, Alex P Reiner, Russell P Tracy, Debby Ngo, Robert E Gerszten, Wanda K O'Neal, Russell P Bowler, NHLBI Trans‐Omics for Precision Medicine (TOPMed) Consortium
发表日期
2020/6
期刊
Proteomics
卷号
20
期号
12
页码范围
1900278
简介
Novel proteomics platforms, such as the aptamer‐based SOMAscan platform, can quantify large numbers of proteins efficiently and cost‐effectively and are rapidly growing in popularity. However, comparisons to conventional immunoassays remain underexplored, leaving investigators unsure when cross‐assay comparisons are appropriate. The correlation of results from immunoassays with relative protein quantification is explored by SOMAscan. For 63 proteins assessed in two chronic obstructive pulmonary disease (COPD) cohorts, subpopulations and intermediate outcome measures in COPD Study (SPIROMICS), and COPDGene, using myriad rules based medicine multiplex immunoassays and SOMAscan, Spearman correlation coefficients range from −0.13 to 0.97, with a median correlation coefficient of ≈0.5 and consistent results across cohorts. A similar range is observed for immunoassays in the …
学术搜索中的文章
LM Raffield, H Dang, KA Pratte, S Jacobson… - Proteomics, 2020